Seeking Alpha
  • Today - Thursday, April 24, 2014

  • 6:32 PM
    • Total revenues: $570M (+10.9%), revenues net of acquisitions and recalls/returns: $519.8M (+6.3%), gross profit: $255.5M (+10.1%), EPS: $0.91 (+7.1%).
    • U.S. revenues: $392.1M (+7.8%), international revenues: $177.9M (+18.5%).
    • CF Ops: $144.5M (+47.1%).
    • (SRCL)
    | Comment!
  • 6:21 PM
    • Revenues: $784.8 (+15%), net income: $110M (0%), EPS: $0.31 (-50%)
    • Bookings: $910.2M (+14%).
    • CF Ops: $155.8M (-27.1%)
    • Days sales outstanding: 66 (-4.3%).
    • Total backlog: $9.24B (+22%).
    • Q2 guidance:
    • Revenues: $790M - $830M.
    • New business bookings: $1B - $1.06B.
    • Adjusted EPS: $0.36 - $0.37 (includes share-based comp expense).
    • Updated 2014 guidance:
    • Revenues: $3.25B - $3.4B, up from $3.2B - $3.4B.
    • Adjusted EPS: $1.51 - $1.55 (includes share-based comp expense).
    • (CERN)
    • Press release
    | Comment!
  • 5:27 PM
    • Zogenix (ZGNX +1.1%) sells its Sumavel DosePro migraine therapy business to Endo International (ENDP -0.3%) for $85M and milestone payments related to sales and manufacturing of up to $20M.
    • Endo will puchase Zogenix's DosePro finished goods inventory for $5M and will support the latter's continued manufacturing of the product with a working capital loan of $7M.
    • The product was launched in January 2010. Net sales in 2013 were $31.7M.
    • Endo obtains global rights to the product and assumes responsibility for royalty payments to Aradigm on sales of Sumavel DosePro. Zogenix retains ownership of the technology, all DosePro manufacturing assets and responsibility for the supply chain.
    • 8-K
    | Comment!
  • 5:05 PM
    • Universal Health Services Inc. (UHS): Q1 EPS of $1.36 beats by $0.13.
    • Revenue of $1.92B (+4.9% Y/Y) misses by $10M.
    • Press Release
    | Comment!
  • 5:00 PM
    • Revenues: $522.4M (+5.2%), net income: $60.3M (-58.1%), EPS: $0.56 (-54.8%). Q1'13 income included $83.6M from Medtronic (U.S. Anderson patent litigation).
    • Transcatheter heart valve revenues: $189.2M (+11.5%).
    • Critical Care product group revenues: $130.6M (+1.2%).
    • CF Ops: $138.9M (+59.1%).
    • Q2 Guidance:
    • Revenues: $525M - $565M.
    • EPS: $0.71 - $81 ex items.
    • Updated 2014 guidance:
    • Revenues: $2.05B - $2.25B.
    • EPS: $3.10 ex items.
    • (EW +0.4%)
    • Press release
    | Comment!
  • 4:46 PM
    • Revenues: $449.5M (+2.5%), gross profit: $101.5M (+4.7%), operating income: $61.2M (+10.6%), net income: $34M (+11.7%), EPS: $0.38 (+11.8%).
    • Animal hospital revenues: $351.6M (+3.2%).
    • Same-store gross profit margin: 14.4% (+5.9%).
    • Laboratory internal revenue: $88.4M (+1.9%); gross profit margin: 48.6% (0%), operating margin: 39.6% (+0.3%).
    • Company confirms the 2014 guidance that was provided on February 13.
    • (WOOF)
    • Press release
    | Comment!
  • 4:42 PM
    • ABAXIS, Inc. (ABAX): FQ4 EPS of $0.17 misses by $0.02.
    • Revenue of $42.04M (-15.8% Y/Y) misses by $3.7M.
    • Press Release
    | Comment!
  • 4:38 PM
    • Merit Medical Systems (MMSI): Q1 EPS of $0.12 misses by $0.01.
    • Revenue of $119.23M (+14.8% Y/Y) beats by $4.69M.
    • Press Release
    | Comment!
  • 4:32 PM
    • Q1 revenues: $531.9M (+5.2%), EPS: $0.30 (+7.1%), operating income: $50.7M (+41.2%).
    • Human Health: revenues: $299.5M (+6.5%), operating income: $43.1M (+72.4%).
    • Environmental Health: revenues: $232.4M (+3.8%), operating income: $21.5M (+3.9%).
    • CF Ops: $67.9M (+512%). Increase due to lower pension funding and reduced royalty payments.
    • Updated 2014 guidance: EPS: $1.91 - $1.95.
    • Press release
    • (PKI)
    | Comment!
  • 4:32 PM
    • AtriCure, Inc. (ATRC): Q1 EPS of -$0.31 misses by $0.09.
    • Revenue of $24.8M (+27.6% Y/Y) beats by $1.44M.
    • Press Release
    | Comment!
  • 4:27 PM
    • PerkinElmer, Inc. (PKI): Q1 EPS of $0.46 beats by $0.02.
    • Revenue of $533.4M (+5.1% Y/Y) beats by $2.09M.
    • Press Release
    | Comment!
  • 4:24 PM
    • Healthways, Inc. (HWAY): Q1 EPS of -$0.07 beats by $0.04.
    • Revenue of $176.8M (+7.0% Y/Y) misses by $0.33M.
    • Press Release
    | Comment!
  • 4:19 PM
    • Fiscal Q4 revenues: $42M (-16%), net income: $3.7M (-44.8%).
    • Fiscal year revenues: $171.9M (-8%), net income: $14.2M (-48.4%).
    • Medical reagent disc sales for fiscal Q4 were 740K (+37%) and 2.7M (+10%) for FY14
    • Medical market revenues were $7.1M and $28.1M for fiscal Q4 and the FY14, respectively.
    • International sales for the same two periods were $9.2M and $35.3M.
    • Quick assets totaled $121.2M as of March 31.
    • BOD declares a $0.10 quarterly dividend payable June 17 to shareholders of record June 3.
    • 217 mutual funds have positions, down from 230 a year ago.
    • (ABAX -1.3%)
    | Comment!
  • 4:05 PM
    • Edwards Lifesciences Corp (EW): Q1 EPS of $0.76 beats by $0.07.
    • Revenue of $522.4M (+5.2% Y/Y) misses by $0.7M.
    • Press Release
    | Comment!
  • 4:04 PM
    • The FDA approves Roche's (RHHBY -0.2%) cobas HPV molecular diagnostic assay for use as a stand-alone screening test for HPV. Previously, the product was cleared only for use in conjunction with or as a follow-on diagnostic to a PAP test for women at least 30 years old.
    • The test detects HPV types 16 and 18 which are responsible for 70% of cervical cancer. It detects 12 other high risk types in a pooled result.
    • The clinical trial also showed that utilizing the automated cobas HPV test as a first-line diagnostic and then reflexing to a cervical cytology (PAP) test would enable clinicians to detect more disease and eliminate unnecessary follow-up procedures.
    | Comment!
  • 11:58 AM
    | Comment!
  • 10:44 AM
    • RTI Surgical (RTIX +4.4%) raises its full year revenue guidance to $248M - $253M from $245M - $250M and EPS expectations to $0.07 - $0.09 from $0.06 - $0.08.
    • Q2 guidance calls for revenues of $62M - $63M and EPS of $0.02.
    • Q1 highlights were:
    • Revenues: $60.7M (sports med: $11.4M, surgical specialties: $7.3M, dental: $4.6M).
    • U.S. revenues: $54.8M, international: $5.9M.
    | Comment!
  • 10:27 AM
    • Q1 revenues: $1.75B (-2.3%).
    • Income from continuing operations: $104M (-10.3%).
    • EPS: $0.71 (-0.1%).
    • Value per requisition decreased 2.8% due to changes in reimbursement and last year's toxicology acquisition.
    • Harsh winter weather decreased revenues and volume by 2% and adjusted EPS by $0.11.
    • CF Ops: $84M (+$78.7%).
    • 2014 guidance:
    • Revenue growth: 2% - 4%.
    • Adjusted EPS: $3.95 - $4.15.
    • CF Ops: $300M.
    • CAPEX: $300M.
    • (DGX -2%)
    | Comment!
  • 10:01 AM
    • Despite its disagreement with the DOJ over alleged misconduct, Amedisys (AMED +0.3%) finalizes the settlement by agreeing to pay $150M plus interest. $115M plus interest is due by May 2, 2014 and $35M plus interest is due by October 23, 2014.
    • The company charged the settlement costs in Q3 2013.
    • It must also pay ~$3.9M in attorneys fees and expenses of various qui tam relators.
    • The investigation focused on Medicare reimbursement for home health services by certain Amedisys care centers from January 1, 2008 through December 31, 2010.
    • The settlement also resolves a Stark Law issue regarding care coordination services provided to a physician practice group in exchange for compensation that was inconsistent with the fair market value of the services during the period April 1, 2008 - April 30, 2012.
    • 8-K
    | Comment!
  • 9:24 AM
    • Revenues were $181.9M (-2.7%), EPS: $0.31 (-19.4%).
    • International sales: $94.6M.
    • EBITDA yield was 15.4%.
    • CF Ops: $17M (+214.8%).
    • Q2 guidance:
    • Revenues: $190M - $195M.
    • EPS: $0.44 - $0.48.
    • 2014 guidance:
    • Revenues: $770M - $780M.
    • EPS: $1.90 - $2.00.
    • Guidance excludes special items related to the relocation of manufacturing, litigation and other costs.
    • (CNMD)
    | Comment!
DJIA (DIA) S&P 500 (SPY)